Bladder Cancer Education
Urothelial carcinoma treatment has been transformed by immunotherapy, ADCs, and FGFR-targeted therapy. Knowledge Med sessions help community providers navigate these advances through interactive case simulations — from perioperative immunotherapy to biomarker-driven treatment selection.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing bladder & urothelial cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Integrating perioperative immunotherapy for muscle-invasive disease
- Selecting maintenance avelumab after first-line chemotherapy
- Identifying candidates for enfortumab vedotin and other ADCs
- Applying FGFR testing and erdafitinib in appropriate patients
What Sessions Cover
Knowledge Med Bladder & Urothelial Cancer sessions use interactive case simulations to address these topics and more.
- Perioperative immunotherapy in muscle-invasive bladder cancer
- First-line therapy and maintenance strategies in advanced urothelial cancer
- ADCs and novel agents: enfortumab vedotin, sacituzumab govitecan
- Biomarker-driven approaches: FGFR, PD-L1, and Nectin-4
Interactive Bladder & Urothelial Cancer Sessions
Case Simulations
Work through realistic bladder & urothelial cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Bladder & Urothelial Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Bladder & Urothelial Cancer Session
Third-party, non-promotional bladder & urothelial cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session